Latest From Biogen Inc.
Samsung Bioepis has entered a fifth continent by launching its Brenzys etanercept biosimilar in Brazil, as part of global expansion plans for the business.
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.
In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared with the $686m companies raised in 2018 overall. Experts says this "rude health" should continue for the next two to three years, at least.
- Gene Therapy, Cell Therapy
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Biogen Idec Inc.
- Biogen Inc.
- Idec Pharmaceutical Corp.
- North America
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
Michel Vounatsos, CEO
Jeffrey Capello, EVP, CFO
Alfred W Sandrock, Jr., MD, PhD, EVP, CMO
Michael Ehlers, MD, PhD, EVP, R&D
Daniel Karp, EVP, Corp. Dev.
Chirfi Guindo, EVP & Head, Global Mktg.
- Contact Info
Phone: (617) 679-2000
225 Binney St.
Cambridge, MA 02142
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.